Meta-analysis of 8 studies (429 younger patients with AML) of hypomethylating agents plus venetoclax: pooled CR/CRi 66%, MRD negativity 69%, 1-year OS 75% and EFS 59%; 66% proceeded to HSCT. No direct comparator.
Meta-analysisn = 429
Perrone et al. Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm